Geninus Inc.
GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of genome analysis solutions in South Korea, the United States, and Asia. It offers tarhet and biomarker discovery; AI digital pathology; single cell analysis; and spatial and in-situ transcriptomics services; and SPACEINSIGHT, a cutting-edge cloud based integrated analysis platform. It… Read more
Geninus Inc. - Asset Resilience Ratio
Geninus Inc. (389030) has an Asset Resilience Ratio of 13.34% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Geninus Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Geninus Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩5.00 Billion | 13.34% |
| Total Liquid Assets | ₩5.00 Billion | 13.34% |
Asset Resilience Insights
- Moderate Liquidity: Geninus Inc. has 13.34% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Geninus Inc. Industry Peers by Asset Resilience Ratio
Compare Geninus Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Geninus Inc. (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Geninus Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.11% | ₩5.00 Billion | ₩33.09 Billion | -4.63pp |
| 2023-12-31 | 19.74% | ₩8.00 Billion | ₩40.53 Billion | -47.35pp |
| 2022-12-31 | 67.09% | ₩30.75 Billion | ₩45.83 Billion | -10.15pp |
| 2021-12-31 | 77.24% | ₩44.85 Billion | ₩58.06 Billion | +5.82pp |
| 2020-12-31 | 71.42% | ₩21.71 Billion | ₩30.40 Billion | +24.62pp |
| 2019-12-31 | 46.80% | ₩6.08 Billion | ₩12.98 Billion | +4.83pp |
| 2018-12-31 | 41.97% | ₩1.40 Billion | ₩3.34 Billion | -- |